{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:12:26Z","timestamp":1784913146181,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Fund of China","award":["81170413"],"award-info":[{"award-number":["81170413"]}]},{"name":"Natural Science Fund of China","award":["81400637"],"award-info":[{"award-number":["81400637"]}]},{"DOI":"10.13039\/501100002858","name":"Chinese Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2014M560721"],"award-info":[{"award-number":["2014M560721"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"Chinese Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2015T80984"],"award-info":[{"award-number":["2015T80984"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinesisch-Deutsches Zentrum f\u00fcr Wissenschaftsf\u00f6rderung","award":["GZ 1065"],"award-info":[{"award-number":["GZ 1065"]}]},{"DOI":"10.13039\/100012542","name":"Science and Technology Support Program of Sichuan province","doi-asserted-by":"crossref","award":["2016SZ0041"],"award-info":[{"award-number":["2016SZ0041"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abnormal angiogenesis is critical for portal hypertension in cirrhosis. Except for etiological treatment, no efficient medication or regime has been explored to treat the early stage of cirrhosis when angiogenesis is initiated or overwhelming. In this study, we explored an anti-angiogenesis effort through non-cytotoxic drugs octreotide and celecoxib to treat early stage of cirrhotic portal hypertension in an animal model. Peritoneal injection of thioacetamide (TAA) was employed to induce liver cirrhosis in rats. A combination treatment of celecoxib and octreotide was found to relieve liver fibrosis, portal venous pressure, micro-hepatic arterioportal fistulas, intrahepatic and splanchnic angiogenesis. Celecoxib and octreotide exerted their anti-angiogenesis effect via an axis of cyclooxygenase-2\/prostaglandin E2\/EP-2\/somatostatin receptor-2, which consequently down-regulated phosphorylation of extracellular signal-regulated kinase (p-ERK)\u2013hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1)\u2013vascular endothelial growth factor (VEGF) integrated signaling pathways. In conclusions, combination of celecoxib and octreotide synergistically ameliorated liver fibrosis and portal hypertension of the cirrhotic rats induced by TAA via the inhibition of intrahepatic and extrahepatic angiogenesis. The potential mechanisms behind the regimen may due to the inactivation of p-ERK\u2013HIF-1\u03b1\u2013VEGF signaling pathway.<\/jats:p>","DOI":"10.1007\/s10456-016-9522-9","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T16:47:27Z","timestamp":1467737247000},"page":"501-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats"],"prefix":"10.1007","volume":"19","author":[{"given":"Jin-Hang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Lei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Hang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Mei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Qi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"issue":"3","key":"9522_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2010.03.021","volume":"53","author":"J Bosch","year":"2010","unstructured":"Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC (2010) Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 53(3):558\u2013567. doi:10.1016\/j.jhep.2010.03.021","journal-title":"J Hepatol"},{"issue":"1","key":"9522_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imj.12590","volume":"45","author":"S Bloom","year":"2015","unstructured":"Bloom S, Kemp W, Lubel J (2015) Portal hypertension: pathophysiology, diagnosis and management. Intern Med J 45(1):16\u201326. doi:10.1111\/imj.12590","journal-title":"Intern Med J"},{"issue":"4","key":"9522_CR3","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.27343","volume":"61","author":"M Fernandez","year":"2015","unstructured":"Fernandez M (2015) Molecular pathophysiology of portal hypertension. Hepatology 61(4):1406\u20131415. doi:10.1002\/hep.27343","journal-title":"Hepatology"},{"issue":"5","key":"9522_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","volume":"53","author":"D Thabut","year":"2010","unstructured":"Thabut D, Shah V (2010) Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 53(5):976\u2013980. doi:10.1016\/j.jhep.2010.07.004","journal-title":"J Hepatol"},{"issue":"1","key":"9522_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10456-013-9382-5","volume":"17","author":"SM Blois","year":"2014","unstructured":"Blois SM, Piccioni F, Freitag N, Tirado-Gonzalez I, Moschansky P, Lloyd R, Hensel-Wiegel K, Rose M, Garcia MG, Alaniz LD, Mazzolini G (2014) Dendritic cells regulate angiogenesis associated with liver fibrogenesis. Angiogenesis 17(1):119\u2013128. doi:10.1007\/s10456-013-9382-5","journal-title":"Angiogenesis"},{"issue":"2","key":"9522_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0016-5085(03)00904-1","volume":"125","author":"H Yamamoto","year":"2003","unstructured":"Yamamoto H, Kondo M, Nakamori S, Nagano H, Ki Wakasa, Sugita Y, Chang DJ, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M (2003) JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 125(2):556\u2013571. doi:10.1016\/s0016-5085(03)00904-1","journal-title":"Gastroenterology"},{"issue":"2","key":"9522_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0003319708318378","volume":"60","author":"M Sahin","year":"2009","unstructured":"Sahin M, Sahin E, Gumuslu S (2009) Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60(2):242\u2013253. doi:10.1177\/0003319708318378","journal-title":"Angiology"},{"issue":"1","key":"9522_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00432-010-0869-9","volume":"137","author":"LE Mainetti","year":"2011","unstructured":"Mainetti LE, Rozados VR, Rossa A, Bonfil RD, Scharovsky OG (2011) Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. J Cancer Res Clin Oncol 137(1):151\u2013163. doi:10.1007\/s00432-010-0869-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"9522_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2217\/fon.12.196","volume":"9","author":"HA Perroud","year":"2013","unstructured":"Perroud HA, Rico MJ, Alasino CM, Queralt F, Mainetti LE, Pezzotto SM, Rozados VR, Scharovsky OG (2013) Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 9(3):451\u2013462. doi:10.2217\/fon.12.196","journal-title":"Future Oncol"},{"issue":"2","key":"9522_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10456-012-9260-6","volume":"15","author":"G Allegrini","year":"2012","unstructured":"Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15(2):275\u2013286. doi:10.1007\/s10456-012-9260-6","journal-title":"Angiogenesis"},{"issue":"2","key":"9522_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-015-2947-9","volume":"77","author":"HA Perroud","year":"2016","unstructured":"Perroud HA, Alasino CM, Rico MJ, Mainetti LE, Queralt F, Pezzotto SM, Rozados VR, Graciela Scharovsky O (2016) Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. Cancer Chemother Pharmacol 77(2):365\u2013374. doi:10.1007\/s00280-015-2947-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"9522_CR12","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/jgh.12641","volume":"29","author":"SL Wen","year":"2014","unstructured":"Wen SL, Gao JH, Yang WJ, Lu YY, Tong H, Huang ZY, Liu ZX, Tang CW (2014) Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. J Gastroenterol Hepatol 29(11):1932\u20131942. doi:10.1111\/jgh.12641","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"9522_CR13","doi-asserted-by":"publisher","first-page":"e69309","DOI":"10.1371\/journal.pone.0069309","volume":"8","author":"JH Gao","year":"2013","unstructured":"Gao JH, Wen SL, Yang WJ, Lu YY, Tong H, Huang ZY, Liu ZX, Tang CW (2013) Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PLoS One 8(7):e69309. doi:10.1371\/journal.pone.0069309","journal-title":"PLoS One"},{"issue":"4","key":"9522_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000374099","volume":"33","author":"J Gracia-Sancho","year":"2015","unstructured":"Gracia-Sancho J, Maeso-Diaz R, Bosch J (2015) Pathophysiology and a rational basis of therapy. Dig Dis 33(4):508\u2013514. doi:10.1159\/000374099","journal-title":"Dig Dis"},{"issue":"5A","key":"9522_CR15","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/j.1582-4934.2008.00218.x","volume":"12","author":"M Mejias","year":"2008","unstructured":"Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M (2008) The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. J Cell Mol Med 12(5A):1690\u20131699. doi:10.1111\/j.1582-4934.2008.00218.x","journal-title":"J Cell Mol Med"},{"issue":"1","key":"9522_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/1751-2980.12001","volume":"14","author":"H Tong","year":"2013","unstructured":"Tong H, Li X, Zhang CL, Gao JH, Wen SL, Huang ZY, Wen FQ, Fu P, Tang CW (2013) Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. J Dig Dis 14(1):29\u201337. doi:10.1111\/1751-2980.12001","journal-title":"J Dig Dis"},{"issue":"1","key":"9522_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4161\/cbt.12.1.15730","volume":"12","author":"Y Xie","year":"2011","unstructured":"Xie Y, Chen S, Wang CH, Tang CW (2011) SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. Cancer Biol Ther 12(1):86\u201392. doi:10.4161\/cbt.12.1.15730","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"9522_CR18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","volume":"126","author":"M Fernandez","year":"2004","unstructured":"Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J (2004) Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126(3):886\u2013894","journal-title":"Gastroenterology"},{"issue":"5","key":"9522_CR19","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1053\/jhep.2002.32524","volume":"35","author":"C Corpechot","year":"2002","unstructured":"Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C, Rosmorduc O (2002) Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35(5):1010\u20131021","journal-title":"Hepatology"},{"issue":"6","key":"9522_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1002\/hep.21921","volume":"46","author":"S Tugues","year":"2007","unstructured":"Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, Friedman SL, Carmeliet P, Jimenez W, Morales-Ruiz M (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46(6):1919\u20131926. doi:10.1002\/hep.21921","journal-title":"Hepatology"},{"issue":"5","key":"9522_CR21","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/hep.24238","volume":"53","author":"C Van Steenkiste","year":"2011","unstructured":"Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, Libbrecht L, Olievier K, Schroyen B, Reynaert H, van Grunsven LA, Blomme B, Coulon S, Heindryckx F, De Vos M, Stassen JM, Vinckier S, Altamirano J, Bataller R, Carmeliet P, Van Vlierberghe H, Colle I, Morales-Ruiz M (2011) Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 53(5):1629\u20131640. doi:10.1002\/hep.24238","journal-title":"Hepatology"},{"issue":"4","key":"9522_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/hep.22758","volume":"49","author":"M Mejias","year":"2009","unstructured":"Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4):1245\u20131256. doi:10.1002\/hep.22758","journal-title":"Hepatology"},{"issue":"4","key":"9522_CR23","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.21785","volume":"46","author":"M Fernandez","year":"2007","unstructured":"Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J (2007) Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 46(4):1208\u20131217. doi:10.1002\/hep.21785","journal-title":"Hepatology"},{"issue":"2","key":"9522_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep.24427","volume":"54","author":"D Thabut","year":"2011","unstructured":"Thabut D, Routray C, Lomberk G, Shergill U, Glaser K, Huebert R, Patel L, Masyuk T, Blechacz B, Vercnocke A, Ritman E, Ehman R, Urrutia R, Shah V (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54(2):573\u2013585. doi:10.1002\/hep.24427","journal-title":"Hepatology"},{"issue":"4","key":"9522_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1634\/theoncologist.2012-0388","volume":"18","author":"KR Sampat","year":"2013","unstructured":"Sampat KR, O\u2019Neil B (2013) Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist 18(4):430\u2013438. doi:10.1634\/theoncologist.2012-0388","journal-title":"Oncologist"},{"key":"9522_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.05.004","author":"RS Alameddine","year":"2015","unstructured":"Alameddine RS, Yakan AS, Skouri H, Mukherji D, Temraz S, Shamseddine A (2015) Cardiac and vascular toxicities of angiogenesis inhibitors: the other side of the coin. Crit Rev Oncol Hematol. doi:10.1016\/j.critrevonc.2015.05.004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"9522_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465\u2013477","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"9522_CR28","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/hep.27649","volume":"61","author":"RL Pan","year":"2015","unstructured":"Pan RL, Xiang LX, Wang P, Liu XY, Nie L, Huang W, Shao JZ (2015) Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of Delta-like1. Hepatology 61(5):1708\u20131720. doi:10.1002\/hep.27649","journal-title":"Hepatology"},{"issue":"1","key":"9522_CR29","first-page":"115","volume":"19","author":"R Wang","year":"2013","unstructured":"Wang R, Guo L, Wang P, Yang W, Lu Y, Huang Z, Tang C (2013) Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr Pharm Des 19(1):115\u2013125","journal-title":"Curr Pharm Des"},{"issue":"4","key":"9522_CR30","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1210\/en.2002-220949","volume":"144","author":"T Florio","year":"2003","unstructured":"Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144(4):1574\u20131584. doi:10.1210\/en.2002-220949","journal-title":"Endocrinology"},{"issue":"1","key":"9522_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bbrc.2005.12.175","volume":"341","author":"YQ Wang","year":"2006","unstructured":"Wang YQ, Luk JM, Chu AC, Ikeda K, Man K, Kaneda K, Fan ST (2006) TNP-470 blockage of VEGF synthesis is dependent on MAPK\/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells. Biochem Biophys Res Commun 341(1):239\u2013244. doi:10.1016\/j.bbrc.2005.12.175","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"9522_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nm.3516","volume":"20","author":"AJ O\u2019Brien","year":"2014","unstructured":"O\u2019Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, Karra E, Winstanley A, Alazawi W, Garcia-Martinez R, Cordoba J, Nicolaou A, Gilroy DW (2014) Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 20(5):518\u2013523. doi:10.1038\/nm.3516","journal-title":"Nat Med"},{"issue":"18","key":"9522_CR33","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2165\/11208240-000000000-00000","volume":"71","author":"PL McCormack","year":"2011","unstructured":"McCormack PL (2011) Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71(18):2457\u20132489. doi:10.2165\/11208240-000000000-00000","journal-title":"Drugs"},{"issue":"11","key":"9522_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/gut.2008.157420","volume":"58","author":"YH Paik","year":"2009","unstructured":"Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, An SH, Lee SJ, Lee DK, Han KH, Chon CY, Lee SI, Lee KS, Brenner DA (2009) Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 58(11):1517\u20131527. doi:10.1136\/gut.2008.157420","journal-title":"Gut"},{"issue":"3","key":"9522_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/07357907.2013.877480","volume":"32","author":"MJ Rico","year":"2014","unstructured":"Rico MJ, Perroud HA, Mainetti LE, Rozados VR, Scharovsky OG (2014) Comparative effectiveness of two metronomic chemotherapy schedules-our experience in the preclinical field. Cancer Invest 32(3):92\u201398. doi:10.3109\/07357907.2013.877480","journal-title":"Cancer Invest"},{"issue":"3","key":"9522_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/ajg.2012.467","volume":"108","author":"B Cryer","year":"2013","unstructured":"Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF (2013) GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 108(3):392\u2013400. doi:10.1038\/ajg.2012.467","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"9522_CR37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1478-3231.2011.02739.x","volume":"32","author":"YC Lee","year":"2012","unstructured":"Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS (2012) Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int 32(5):859\u2013866. doi:10.1111\/j.1478-3231.2011.02739.x","journal-title":"Liver Int"}],"updated-by":[{"DOI":"10.1007\/s10456-022-09855-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000}}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-016-9522-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10456-016-9522-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-016-9522-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T13:15:48Z","timestamp":1662815748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10456-016-9522-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["9522"],"URL":"https:\/\/doi.org\/10.1007\/s10456-016-9522-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10456-022-09855-4","asserted-by":"object"}]},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]},"assertion":[{"value":"10 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10456-022-09855-4","URL":"https:\/\/doi.org\/10.1007\/s10456-022-09855-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}